Atara Biotherapeutics, Inc. (ATRA) FinancialsATRAAtara Biotherapeutics, Inc.

Evaluating the bottom line, Atara Biotherapeutics, Inc. maintains a gross margin of 69.68%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -627.46%, while the net margin is -767.30%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ATRA converts its operational activities into shareholder value.

In the context of the broader market, ATRA competes directly with industry leaders such as FBIO and DWTX. With a market capitalization of $81.21M, it holds a significant position in the sector. When comparing efficiency, ATRA's gross margin of 69.68% stands against FBIO's 62.00% and DWTX's N/A. Such benchmarking helps identify whether Atara Biotherapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Atara's gross margin has been strong, reaching 96.85% in Q2 2025, but the company has struggled with net income, reporting a loss of $4.83 million in Q2 2026.